Gabriele Zoppoli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3170688/publications.pdf

Version: 2024-02-01

83	3,018	236612	182168
papers	citations	25 h-index	51 g-index

91	91	91	6085
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 2022, 164, 39-51.	1.3	8
2	Abstract P4-02-02: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. Cancer Research, 2022, 82, P4-02-02-P4-02-02.	0.4	0
3	Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. JCO Precision Oncology, 2022, 6, e2100198.	1.5	0
4	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. Gynecologic Oncology, 2022, 165, 239-247.	0.6	9
5	Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study. Journal of Translational Medicine, 2022, 20, 230.	1.8	0
6	The Multidisciplinary Approach of Rectal Cancer: The Experience of â€œCOMRE Groupâ€•Model. Diagnostics, 2022, 12, 1571.	1.3	0
7	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncology, The, 2021, 22, 476-488.	5.1	179
8	Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. Frontiers in Endocrinology, 2021, 12, 677919.	1.5	16
9	Abstract LB063: Plasma cell-free DNA integrity predicts the achievement of pathological complete response to neoadjuvant chemotherapy in breast cancer patients. , 2021, , .		1
10	Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications. Cancers, 2021, 13, 3460.	1.7	15
11	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 7154.	1.8	5
12	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. Cancers, 2021, 13, 4013.	1.7	31
13	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. JCI Insight, 2021, 6, .	2.3	14
14	Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers. In Vivo, 2021, 35, 635-639.	0.6	2
15	Prospective validation study of prognostic biomarkers to predict adverse outcomes in patients with COVID-19: a study protocol. BMJ Open, 2021, 11, e044497.	0.8	14
16	Development of a hoRizontal data intEgration classifier for NOn-invasive early diAgnosis of breasT cancEr: the RENOVATE study protocol. BMJ Open, 2021, 11, e054256.	0.8	2
17	Lymph node number, surface area and lymph node ratio are important prognostic indicators in neoadjuvant chemoradiotherapy treated rectal cancer. Journal of Clinical Pathology, 2020, 73, 162-166.	1.0	7
18	Development of a predictor of one-year mortality in older patients with cancer by geriatric and oncologic parameters. Journal of Geriatric Oncology, 2020, 11, 610-616.	0.5	4

#	Article	IF	Citations
19	The genomic landscape of metastatic histologic special types of invasive breast cancer. Npj Breast Cancer, 2020, 6, 53.	2.3	27
20	Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature, 2020, 583, 620-624.	13.7	198
21	A modular framework for the development of targeted Covid-19 blood transcript profiling panels. Journal of Translational Medicine, 2020, 18, 291.	1.8	13
22	Sterol synthesis pathway inhibition as a target for cancer treatment. Cancer Letters, 2020, 493, 19-30.	3.2	15
23	Digital analysis of distant and cancer-associated mammary adipocytes. Breast, 2020, 54, 179-186.	0.9	5
24	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
25	Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review. Anticancer Research, 2020, 40, 3543-3550.	0.5	6
26	Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma. PLoS ONE, 2020, 15, e0226595.	1.1	17
27	Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Journal of Oncology, 2020, 2020, 1-10.	0.6	4
28	Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer. Breast Cancer Research and Treatment, 2019, 177, 335-343.	1.1	19
29	Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. Journal of Translational Medicine, 2019, 17, 137.	1.8	13
30	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	3.0	76
31	Squalene epoxidase as a promising metabolic target in cancer treatment. Cancer Letters, 2018, 425, 13-20.	3.2	53
32	Transcriptomic and genomic features of invasive lobular breast cancer. Seminars in Cancer Biology, 2017, 44, 98-105.	4.3	34
33	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nature Communications, 2017, 8, 14944.	5.8	126
34	Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases. Journal of Translational Medicine, 2017, 15, 91.	1.8	15
35	DNA aneuploidy relationship with patient age and tobacco smoke in OPMDs/OSCCs. PLoS ONE, 2017, 12, e0184425.	1.1	14
36	Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2016, 8, 314-336.	6.6	11

#	Article	IF	Citations
37	Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. Scientific Reports, 2016, 6, 19435.	1.6	102
38	Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1872-1881.	0.8	249
39	Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. Methods in Molecular Biology, 2016, 1386, 181-219.	0.4	12
40	Transcription Factors Synergistically Activated at the Crossing of the Restriction Point between G1 and S Cell Cycle Phases. Pathologic Gate Opening during Multi-Hit Malignant Transformation. Nuclear Receptor Research, 2016, 3, .	2.5	0
41	Uncovering the genomic heterogeneity of multifocal breast cancer. Journal of Pathology, 2015, 236, 457-466.	2.1	72
42	Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma. , 2015, 3, .		2
43	Genomic aberrations in young and elderlyÂ breast cancer patients. BMC Medicine, 2015, 13, 266.	2.3	80
44	Genomic DNA Copy Number Aberrations, Histological Diagnosis, Oral Subsite and Aneuploidy in OPMDs/OSCCs. PLoS ONE, 2015, 10, e0142294.	1.1	25
45	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. Oncotarget, 2015, 6, 5041-5058.	0.8	24
46	Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity. Journal of Biological Chemistry, 2014, 289, 34189-34204.	1.6	64
47	Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions. Gynecologic Oncology, 2014, 132, 389-396.	0.6	9
48	Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes. Tumori, 2014, 100, 128-35.	0.6	1
49	The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. World Journal of Surgical Oncology, 2013, 11, 292.	0.8	18
50	Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors. Current Cancer Drug Targets, 2012, 12, 303-315.	0.8	18
51	DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment. Current Cancer Drug Targets, 2012, 12, 356-371.	0.8	34
52	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15030-15035.	3.3	252
53	Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond. Current Cancer Drug Targets, 2012, 12, 316-328.	0.8	25
54	Seasonal and pandemic (A/H1N1 2009) MF-59â€“adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood, 2012, 120, 1954-1957.	0.6	16

#	Article	IF	Citations
55	The NAD+-dependent Histone Deacetylase SIRT6 Promotes Cytokine Production and Migration in Pancreatic Cancer Cells by Regulating Ca2+ Responses. Journal of Biological Chemistry, 2012, 287, 40924-40937.	1.6	151
56	CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene, 2012, 31, 403-418.	2.6	20
57	Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer. Molecular Medicine, 2012, 18, 1519-1526.	1.9	24
58	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. Pituitary, 2012, 15, 209-214.	1.6	7
59	On biomarkers and pathways in rectal cancer: What's the target?. World Journal of Gastrointestinal Surgery, 2012, 4, 275.	0.8	2
60	Dynamic Simulations of Pathways Downstream of TGFÎ², Wnt and EGF-Family Growth Factors, in Colorectal Cancer, including Mutations and Treatments with Onco-Protein Inhibitors. SIMAI Springer Series, 2012, , 127-142.	0.4	0
61	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. PLoS ONE, 2011, 6, e22739.	1.1	68
62	Identification of a Predominant Co-Regulation among Kinetochore Genes, Prospective Regulatory Elements, and Association with Genomic Instability. PLoS ONE, 2011, 6, e25991.	1.1	20
63	Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. Leukemia Research, 2011, 35, 1472-1476.	0.4	15
64	Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. Journal of Translational Medicine, 2011, 9, 174.	1.8	85
65	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkinâ€™s Lymphoma Patients Treated with Rituximab-Containing Regimens. Journal of Immunology, 2011, 186, 6044-6055.	0.4	93
66	Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. Nucleic Acids Research, 2011, 39, 6620-6632.	6.5	22
67	Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition. Current Cancer Drug Targets, 2010, 10, 168-175.	0.8	26
68	Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era. International Journal of Hematology, 2010, 91, 342-344.	0.7	6
69	Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Experimental Hematology, 2010, 38, 979-988.	0.2	48
70	Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression. PLoS ONE, 2010, 5, e9024.	1.1	35
71	Gynaecomastia: The Anastrozole Paradox. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 205-6.	0.4	1
72	Iodized Oil Pleural Effusion in a Patient Previously Treated With Transarterial Chemoembolization for Hepatocellular Carcinoma. Chest, 2010, 138, 193-195.	0.4	7

#	Article	IF	Citations
73	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS ONE, 2009, 4, e7897.	1.1	143
74	Purpura as the Initial Presentation for Small-Cell Lung Cancer. Onkologie, 2009, 32, 9-9.	1.1	3
75	Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. Cancer Biology and Therapy, 2009, 8, 263-271.	1.5	21
76	Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 816-826.	1.3	90
77	Paralytic Ileus and Liver Failureâ€"An Unusual Presentation of Advanced Erythropoietic Protoporphyria. Digestive Diseases and Sciences, 2009, 54, 411-415.	1.1	12
78	From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients. British Journal of Haematology, 2009, 144, 969-970.	1.2	9
79	APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood, 2009, 113, 6035-6037.	0.6	24
80	Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.. Blood, 2009, 114, 4404-4404.	0.6	0
81	Monotherapy with Pegylated Interferon Alphaâ€2a in Hemodialyzed Patients with Chronic Hepatitis C. Dialysis and Transplantation, 2008, 37, 204-208.	0.2	2
82	A novel Bim-BH3-derived Bcl-XL inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle, 2008, 7, 3211-3224.	1.3	32
83	Soluble molecules and bone metabolism in multiple myeloma: a review. Clinical Cases in Mineral and Bone Metabolism, 2008, 5, 67-70.	1.0	2